325 related articles for article (PubMed ID: 33092443)
1. Salvage camrelizumab plus apatinib for relapsed esophageal neuroendocrine carcinoma after esophagectomy: a case report and review of the literature.
Liu L; Liu Y; Gong L; Zhang M; Wu W
Cancer Biol Ther; 2020 Nov; 21(11):983-989. PubMed ID: 33092443
[TBL] [Abstract][Full Text] [Related]
2. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
3. S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature.
Zhang C; Yu GM; Zhang M; Wu W; Gong LB
Medicine (Baltimore); 2020 Jan; 99(3):e18892. PubMed ID: 32011517
[TBL] [Abstract][Full Text] [Related]
4. Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial.
Cheng H; Zong L; Kong Y; Wang X; Gu Y; Cang W; Zhao J; Wan X; Yang J; Xiang Y
Lancet Oncol; 2021 Nov; 22(11):1609-1617. PubMed ID: 34624252
[TBL] [Abstract][Full Text] [Related]
5. Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma.
Yan Z; Yao ZH; Yao SN; Wang HY; Chu JF; Song M; Zhao S; Liu YY
Immunotherapy; 2020 Nov; 12(16):1161-1166. PubMed ID: 32814482
[No Abstract] [Full Text] [Related]
6. Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study.
Yan Z; Ma J; Yao S; Yao Z; Wang H; Chu J; Zhao S; Liu Y
Front Immunol; 2021; 12():727464. PubMed ID: 34899689
[TBL] [Abstract][Full Text] [Related]
7. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.
Mei K; Qin S; Chen Z; Liu Y; Wang L; Zou J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741732
[TBL] [Abstract][Full Text] [Related]
8. Anlotinib plus camrelizumab achieved long-term survival in a patient with metastatic esophageal neuroendocrine carcinoma.
Zhou L; Xu G; Chen T; Wang Q; Zhao J; Zhang T; Duan R; Xia Y
Cancer Rep (Hoboken); 2023 Sep; 6(9):e1855. PubMed ID: 37381647
[TBL] [Abstract][Full Text] [Related]
9. Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy.
Xing P; Wang M; Zhao J; Zhong W; Chi Y; Xu Z; Li J
Thorac Cancer; 2021 Oct; 12(20):2825-2828. PubMed ID: 34409776
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy.
Qiao Y; Zhao C; Li X; Zhao J; Huang Q; Ding Z; Zhang Y; Jiao J; Zhang G; Zhao S
Front Immunol; 2022; 13():953229. PubMed ID: 35911723
[TBL] [Abstract][Full Text] [Related]
11. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.
Xie L; Xu J; Sun X; Guo W; Gu J; Liu K; Zheng B; Ren T; Huang Y; Tang X; Yan T; Yang R; Sun K; Shen D; Li Y
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376724
[TBL] [Abstract][Full Text] [Related]
12. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
Zhang Q; Shao B; Tong Z; Ouyang Q; Wang Y; Xu G; Li S; Li H
BMC Med; 2022 Oct; 20(1):321. PubMed ID: 36184642
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials.
Liang L; Wen Y; Hu R; Wang L; Xia Y; Hu C; Qiao Y; Geng X; Chen T; Fei J; Hui K; Jiang X
Cancer Immunol Immunother; 2019 Sep; 68(9):1467-1477. PubMed ID: 31451841
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-1 antibody camrelizumab plus doxorubicin showed durable response in pulmonary sarcomatoid carcinoma: Case report and literature review.
Kong F; Wang W; Gong L; Wu W; Liu Y
J Clin Pharm Ther; 2020 Dec; 45(6):1489-1496. PubMed ID: 32776600
[TBL] [Abstract][Full Text] [Related]
16. Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.
Jing C; Wang J; Zhu M; Bai Z; Zhao B; Zhang J; Yin J; Yang X; Liu Z; Zhang Z; Deng W
Cancer Immunol Immunother; 2022 Nov; 71(11):2597-2608. PubMed ID: 35304622
[TBL] [Abstract][Full Text] [Related]
17. First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study.
Chen X; Xu H; Chen X; Xu T; Tian Y; Wang D; Guo F; Wang K; Jin G; Li X; Wang R; Li F; Ding Y; Tang J; Fang Y; Zhao J; Liu L; Ma L; Meng L; Hou Z; Zheng R; Liu Y; Guan N; Zhang B; Tong S; Chen S; Li X; Shu Y
Signal Transduct Target Ther; 2024 Mar; 9(1):73. PubMed ID: 38528050
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, phase 2 study.
Liu J; Li J; Lin W; Shao D; Depypere L; Zhang Z; Li Z; Cui F; Du Z; Zeng Y; Jiang S; He P; Gu X; Chen H; Zhang H; Lin X; Huang H; Lv W; Cai W; Liang W; Liang H; Jiang W; Wang W; Xu K; Cai W; Wu K; Lerut T; Fu J; He J
Int J Cancer; 2022 Jul; 151(1):128-137. PubMed ID: 35188268
[TBL] [Abstract][Full Text] [Related]
19. Response to apatinib and camrelizumab combined treatment in a radioiodine refractory differentiated thyroid cancer patient resistant to prior anti-angiogenic therapy: A case report and literature review.
Li J; Zhang X; Mu Z; Sun D; Sun Y; Lin Y
Front Immunol; 2022; 13():943916. PubMed ID: 36003403
[TBL] [Abstract][Full Text] [Related]
20. [A Case of Neuroendocrine Carcinoma of the Esophagus Treated with Neoadjuvant Chemotherapy Comprising 5-Fluorouracil plus Cisplatin].
Muroya T; Wajima N; Akasaka H; Hasebe T; Yakoshi Y; Yachi T; Akaishi T; Sato K; Mitsuhashi Y; Hakamada K
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2184-2186. PubMed ID: 28133263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
